5/18/2010
In June 2000, Brian Cunningham founded SRU Biosystems with the goal of making biosensors and detection systems to be used in pharmaceutical research and diagnostic tests. Nearly a decade after it was founded, the company has unveiled its BIND SCANNER, a biosensor detection instrument that Cunningham helped develop. The machine has wide applications in pharmaceutical development and basic cell research.
Written by
In June 2000, Brian Cunningham founded SRU Biosystems with the goal of making biosensors and detection systems to be used in pharmaceutical research and diagnostic tests. Nearly a decade after it was founded, the company has unveiled its BIND SCANNER, a biosensor detection instrument that Cunningham helped develop. The machine has wide applications in pharmaceutical development and basic cell research.
The company’s first set of products, which were first released in the early 2000s, were geared toward detecting interactions between biomolecules. The products measured interactions between proteins and DNA and the effects of different drug compounds on those interactions.
“Now the products are in use worldwide for helping make the process of drug discovery more efficient,” explained Cunningham, who is an associate professor in electrical and computer engineering.
With the recent increase in interest in the effects of drugs on cells, SRU Biosystems has created its BIND SCANNER, a detection system that uses biosensors to study cells in a new way.
Cunningham first published a paper on this method in 2004, and an early prototype of the machine has been tested and used in the Micro and Nanotechnology Laboratory's Bio-Nano Lab for the past five years.
In the BIND SCANNER, cells are grown on the biosensor surface. The biosensors are designed to measure changes in reflected wavelength if something, like a cell, attaches to them.